Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 282,012 shares, an increase of 375.6% from the June 15th total of 59,293 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 392,720 shares, the short-interest ratio is presently 0.7 days.

Fresenius SE & Co. Price Performance

Shares of FSNUY stock traded up $0.06 during trading hours on Friday, hitting $12.18. 78,030 shares of the company’s stock were exchanged, compared to its average volume of 221,486. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41. The firm has a market cap of $27.44 billion, a P/E ratio of 16.24 and a beta of 0.63. The firm has a 50 day moving average of $11.42 and a two-hundred day moving average of $13.02. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to analyst estimates of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. Sell-side analysts forecast that Fresenius SE & Co. will post 1.03 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating, According to MarketBeat, Fresenius SE & Co. currently has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.